Testing Gut Bacteria from Young People as a Potential T1D Treatment

Growing evidence suggests that the composition of bacteria living in our gut—called the microbiota—may influence type 1 diabetes development and management. When this microbial community becomes imbalanced, a condition called dysbiosis, it may contribute to blood sugar control problems and immune system dysfunction in people with T1D.

Fecal microbiota transplantation (FMT) is an approach where healthy bacteria from a donor are transferred to a recipient, with the goal of restoring a healthier microbial balance. Scientists hypothesize that using bacteria from young, healthy donors might help remodel the gut ecosystem in adults with T1D.

This is a single-center, randomized, double-blind, placebo-controlled pilot trial designed to enroll adults with type 1 diabetes who currently have suboptimal blood sugar control. Participants will receive either youth-derived fecal microbiota transplantation (yFMT) in capsule form or a placebo.

The study will evaluate three main areas: feasibility (can the approach be carried out as designed?), safety (does it cause harm?), and preliminary efficacy (does it show promise in improving outcomes?).

The primary goal is to see whether participants receiving yFMT achieve better blood sugar control at 12 weeks compared to placebo, measured by standard metrics like HbA1c and continuous glucose monitoring data.

Researchers will also examine changes in C-peptide (a marker of remaining insulin production), immune responses, infection markers, and the composition of gut bacteria itself. Additionally, they will measure metabolites—chemical byproducts produced by bacteria—including short-chain fatty acids and bile acids, which may influence blood sugar metabolism.

The study will track how many people enroll, how many complete the study, whether participants take the treatment as prescribed, and whether they report it as acceptable.

This pilot study is an important early step in exploring whether modifying the gut microbiota could help manage type 1 diabetes. Pilot trials are designed to answer basic questions about feasibility and safety before larger, more definitive studies are undertaken.

The findings will help researchers understand whether youth-derived fecal microbiota transplantation warrants further investigation and what outcomes should be measured in future research. However, this is preliminary evidence, and results from a pilot study do not yet prove whether the approach will be effective for broader use.

Source: PloS one. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.